21 C.F.R. § 60.24

Revision of regulatory review period determinations

Read at: eCFRecfr.gov CornellLII GovInfogovinfo.gov CasesGoogle Scholar

(a) Any person may request a revision of the regulatory review period determination within 60 days after its initial publication in the Federal Register. The request shall be sent to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. The request shall specify the following:

(1) The type of action requested;

(2) The identity of the product;

(3) The identity of the applicant;

(4) The FDA docket number; and

(5) The basis for the request for revision, including any documentary evidence.

(b) Unless the applicant is the person requesting the revision, the applicant shall respond to the request within 15 days. In responding to the request, the applicant may submit information which is relevant to the events during the regulatory review period but which was not included in the original patent term restoration application. A request for a revision is not equivalent to a due diligence petition under § 60.30 or a request for a hearing under § 60.40. If no response is submitted, FDA will decide the matter on the basis of the information in the patent term restoration application, request for revision, and FDA records.

(c) FDA shall apply the provisions of § 60.22 in considering the request for a revision of the regulatory review period determination. lf FDA revises its prior determination, FDA will notify PTO of the revision, send a copy of this notification to the applicant, and publish the revision in the Federal Register, including a statement giving the reasons for the revision.

[53 FR 7305, Mar. 7, 1988, as amended at 59 FR 14364, Mar. 28, 1994; 67 FR 9585, Mar. 4, 2002]
Notes of Decisions
Cited in 3 cases (1 in the last 5 years), 1995–2024 · leading case: Aktiebolaget Astra v. Bruce A. Lehman, Comm'r of Patents & Trademarks, 71 F.3d 1578 (Fed. Cir. 1995).
Aktiebolaget Astra v. Bruce A. Lehman, Comm'r of Patents & Trademarks, 71 F.3d 1578 (Fed. Cir. 1995). “Astra acknowledges its awareness of its opportunity to contest the Secretary’s determination yet did not request a revision or request a hearing pursuant to 21 C.F.R. §§ 60.24 , 60.26. Astra, having given up its forum with the Secretary, now wishes to proceed against the…”
Boehringer Ingelheim Pharma Gmbh & Co. Kg v. United States Food & Drug Admin., 195 F. Supp. 3d 366 (D.D.C. 2016). “” 21 C.F.R. § 60.24 (a). Boehringer did so on June 27, 2012, requesting that date dividing the testing and approval phases be shifted earlier to December 15, 2009, the date that it first claimed it had submitted all materials necessary for FDA review.”
Nissan Chem. Corp. v. U.S. Food & Drug Admin. (D.D.C. 2024). “In April 2018, Nissan submitted a request for revision of the FDA’s regulatory review period determination, as permitted by 21 C.F.R. § 60.24 (a). A.R. 1836-44. In its revision request, Nissan noted that it previously submitted February 19, 2010 as the start date for the testing…”
Annotations are extracted automatically from the opinions in the Syfert caselaw corpus and ranked by authority, recency, and treatment. Dots show Syfertize treatment of the citing case itself.